134 related articles for article (PubMed ID: 18828932)
1. Putting National Institute for Health and Clinical Excellence guidance into practice: a cost minimization model of a national roll-out of liquid based cytology in England.
Stoykova B; Kuzmanov G; Dowie R
Int J Technol Assess Health Care; 2008; 24(4):391-8. PubMed ID: 18828932
[TBL] [Abstract][Full Text] [Related]
2. Liquid-based cytology can improve efficiency of cervical smear readers: evidence from timing surveys in two NHS cytology laboratories.
Dowie R; Stoykova B; Crawford D; Desai M; Mather J; Morgan K; Shirt M
Cytopathology; 2006 Apr; 17(2):65-72. PubMed ID: 16548990
[TBL] [Abstract][Full Text] [Related]
3. From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap.
Legood R; Wolstenholme J; Gray A
Health Policy; 2009 Feb; 89(2):193-200. PubMed ID: 18619702
[TBL] [Abstract][Full Text] [Related]
4. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
5. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
6. The impact of the introduction of liquid based cytology on the variation in the proportion of inadequate samples between GP practices.
Harrison WN; Teale AM; Jones SP; Mohammed MA
BMC Public Health; 2007 Aug; 7():191. PubMed ID: 17678533
[TBL] [Abstract][Full Text] [Related]
7. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
Dietrich ES
Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
[TBL] [Abstract][Full Text] [Related]
8. Cervical cytology practice guideline. American Society of Cytopathology.
Diagn Cytopathol; 2001 Jul; 25(1):3-24. PubMed ID: 11466809
[No Abstract] [Full Text] [Related]
9. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
Eddama O; Coast J
Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
[TBL] [Abstract][Full Text] [Related]
10. An analysis of the costs of implementing the National Newborn Hearing Screening Programme in England.
Uus K; Bamford J; Taylor R
J Med Screen; 2006; 13(1):14-9. PubMed ID: 16569300
[TBL] [Abstract][Full Text] [Related]
11. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
Trowman R; Chung H; Longson C; Littlejohns P; Clark P
Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
[TBL] [Abstract][Full Text] [Related]
12. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
13. Has NICE been nice to cancer?
Summerhayes M; Catchpole P
Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
[TBL] [Abstract][Full Text] [Related]
14. The NHS as an insurer.
Vaithianathan R; Lewis G
J Health Serv Res Policy; 2010 Jul; 15(3):171-3. PubMed ID: 20203080
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.
Suárez E; Smith JS; Bosch FX; Nieminen P; Chen CJ; Torvinen S; Demarteau N; Standaert B
Vaccine; 2008 Sep; 26 Suppl 5():F29-45. PubMed ID: 18992380
[TBL] [Abstract][Full Text] [Related]
16. Identifying and controlling for program-level differences in comparative cost analysis: lessons from the economic evaluation of the National Breast and Cervical Cancer Early Detection Program.
Subramanian S; Ekwueme DU; Gardner JG; Bapat B; Kramer C
Eval Program Plann; 2008 May; 31(2):136-44. PubMed ID: 18359084
[TBL] [Abstract][Full Text] [Related]
17. Bland dyskaryosis: a new pitfall in liquid-based cytology.
Denton K; Rana DN; Lynch MA; Desai MS
Cytopathology; 2008 Jun; 19(3):162-6. PubMed ID: 18177415
[TBL] [Abstract][Full Text] [Related]
18. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
Schlander M
J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
[TBL] [Abstract][Full Text] [Related]
19. Policy implications of rationalization of statin use in Lithuania.
Kadusevicius E; Jankauskiene D; Paulauskaite I; Slapikas R
Int J Technol Assess Health Care; 2009 Jul; 25(3):419-24. PubMed ID: 19619363
[TBL] [Abstract][Full Text] [Related]
20. Overview of the cytology laboratory: specimen processing through diagnosis.
Joste N
Obstet Gynecol Clin North Am; 2008 Dec; 35(4):549-63; viii. PubMed ID: 19061816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
